Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1613 1635 1636 1638 1642
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18957216 | COMPOSITIONS AND METHODS FOR EFFICIENT IN VIVO DELIVERY | Non-Final OA | President and Fellows of Harvard College |
| 18957270 | COMPOSITIONS AND METHODS FOR EFFICIENT IN VIVO DELIVERY | Non-Final OA | President and Fellows of Harvard College |
| 18334074 | TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | Non-Final OA | President and Fellows of Harvard College |
| 17779953 | SYSTEMS AND METHODS FOR EVALUATING CAS9-INDEPENDENT OFF-TARGET EDITING OF NUCLEIC ACIDS | Non-Final OA | President and Fellows of Harvard College |
| 17783938 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | Final Rejection | Merck Sharp & Dohme LLC |
| 18311796 | PATHWAY INTEGRATION AND EXPRESSION IN HOST CELLS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 19305217 | GUIDED MICROBIAL REMODELING, A PLATFORM FOR THE RATIONAL IMPROVEMENT OF MICROBIAL SPECIES FOR AGRICULTURE | Final Rejection | Pivot Bio, Inc. |
| 18752501 | MULTI-VECTOR RECOMBINASE MEDIATED CASSETTE EXCHANGE | Final Rejection | Genentech, Inc. |
| 18187937 | GUIDE-RNA EXPRESSION SYSTEM FOR A HOST CELL | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18265226 | COMPOSITIONS TARGETING WDR37 AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 16467890 | ORTHOGONAL TRANSCRIPTIONAL SWITCHES DERIVED FROM TET REPRESSOR HOMOLOGS FOR SACCHAROMYCES CEREVISIAE | Non-Final OA | The Johns Hopkins University |
| 16174759 | MANUFACTURING METHOD OF NANODISC COMPRISING AN OLFACTORY RECEPTOR PROTEIN AND NANODISC COMPRISING AN OLFACTORY RECEPTOR PROTEIN MANUFACTURED BY THE SAME | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18257504 | CHEMICALLY MODIFIED CRISPR-CAS13 GUIDE RNAS | Non-Final OA | New York University |
| 17756078 | LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF T CELLS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18267144 | METHOD FOR PROGRAMMABLE CONTROL OF RNA TRANSCRIPT LEVELS WITH AUTOREGULATED CRISPR-CAS13D | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17921027 | IMPROVED CAS 12A/NLS MEDIATED THERAPEUTIC GENE EDITING PLATFORMS | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17815711 | GENOME ENGINEERING THE HUMAN IMMUNOGLOBULIN LOCUS TO EXPRESS RECOMBINANT BINDING DOMAIN MOLECULES | Non-Final OA | University of Southern California |
| 18014692 | USE OF SATIVENE, AND RECOMBINANT BIOCONTROL FUNGUS AND MUSCARDINE CADAVER AND USE THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 17601537 | Methods for integrating a donor DNA sequence into the genome of bacillus using linear recombinant DNA constructs and compositions thereof | Non-Final OA | DANISCO US INC |
| 17995539 | REAWAKENING OF DORMANT TUMOR CELLS BY MODIFIED LIPIDS DERIVED FROM STRESS ACTIVATED NEUTROPHILS | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 18262438 | COMPOUNDS AND METHODS FOR REDUCING DUX4 EXPRESSION | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 18283589 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 17926369 | Method for Preparing Combinatorial Library of Multi-Modular Biosynthetic Enzyme Gene | Non-Final OA | Spiber Inc. |
| 17433977 | DIFFERENTIAL KNOCKOUT OF A HETEROZYGOUS ALLELE OF STAT1 | Final Rejection | EMENDOBIO INC. |
| 18282181 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | Non-Final OA | ReCode Therapeutics, Inc. |
| 18251183 | COMPOSITIONS COMPRISING AN RNA GUIDE TARGETING BCL11A AND USES THEREOF | Non-Final OA | Arbor Biotechnologies, Inc. |
| 18038307 | COMPOSITIONS AND METHODS FOR SUPPRESSING MSUT2 | Non-Final OA | THE UNITED STATES GOVERMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18018151 | COMPOSITIONS OF DNA MOLECULES, METHODS OF MAKING THEREFOR, AND METHODS OF USE THEREOF | Non-Final OA | Anjarium Biosciences AG |
| 18007568 | NUCLEIC ACID CONSTRUCTS FOR PROTEIN MANUFACTURE | Non-Final OA | CATALENT PHARMA SOLUTIONS, LLC |
| 17998442 | CLINICALLY APPLICABLE CHARACTERIZATION OF GENETIC VARIANTS BY GENOME EDITING | Non-Final OA | ICO (INSTITUT DE CANCÉROLOGIE DE L'OUEST) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy